Related references
Note: Only part of the references are listed.European Crohn's and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation
Joana Torres et al.
JOURNAL OF CROHNS & COLITIS (2023)
Biologics for Inflammatory Bowel Disease and Their Safety Pregnancy: A Systematic Review and Meta-analysis
Ole Haagen Nielsen et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)
MANTA and MANTA-RAy: Rationale and Design of Trials Evaluating Effects of Filgotinib on Semen Parameters in Patients with Inflammatory Diseases
Wayne J. G. Hellstrom et al.
ADVANCES IN THERAPY (2022)
Pregnancy outcomes following periconceptional or gestational exposure to ustekinumab: Review of cases reported to the manufacturer's global safety database
Uma Mahadevan et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)
Serious Infections in Children Born to Mothers With Inflammatory Bowel Disease With In Utero Exposure to Thiopurines and Anti-Tumor Necrosis Factor
Antoine Meyer et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)
Pregnant women with immune mediated inflammatory diseases who discontinue biologics have higher rates of disease flare
Kenneth D. Allen et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2022)
Pregnancy and neonatal outcomes in women receiving calcineurin inhibitors: A systematic review and meta-analysis
Shintaro Akiyama et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)
Risk Factors for Postpartum Disease Activity in Women With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Gurpreet Malhi et al.
INFLAMMATORY BOWEL DISEASES (2022)
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
Silvio Danese et al.
LANCET (2022)
Safety of Ustekinumab and Vedolizumab During Pregnancy-Pregnancy, Neonatal, and Infant Outcome: A Prospective Multicentre Study
Katarina Mitrova et al.
JOURNAL OF CROHNS & COLITIS (2022)
Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy
Maria Napolitano et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2022)
Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort study
Irit Avni-Biron et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)
Benefits and Risks Associated With Continuation of Anti-Tumor Necrosis Factor After 24 Weeks of Pregnancy in Women With Inflammatory Bowel Disease A Nationwide Emulation Trial
Antoine Meyer et al.
ANNALS OF INTERNAL MEDICINE (2022)
Ozanimod: A Review in Ulcerative Colitis
Julia Paik
DRUGS (2022)
Factors Associated with Inflammatory Bowel Disease Flare During Pregnancy Among Women with Preconception Remission
Amihai Rottenstreich et al.
DIGESTIVE DISEASES AND SCIENCES (2021)
Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease
Uma Mahadevan et al.
GASTROENTEROLOGY (2021)
The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics
Dan-in Jang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program
Krzysztof W. Selmaj et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)
Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre population-based cohort study
Mette Julsgaard et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)
Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and/or anti-TNF: a French nationwide study 2010-2018
Antoine Meyer et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)
Pregnancy and neonatal outcomes in women with immune mediated inflammatory diseases exposed to anti-tumor necrosis factor-a during pregnancy: A systemic review and meta-analysis
Liana Barenbrug et al.
JOURNAL OF AUTOIMMUNITY (2021)
Systematic review and meta-analysis: Safety of vedolizumab during pregnancy in patients with inflammatory bowel disease
Conor Bell et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2021)
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial
Brian G. Feagan et al.
LANCET (2021)
The Influence of Disease Activity on Pregnancy Outcomes in Women With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
Min-A Kim et al.
JOURNAL OF CROHNS & COLITIS (2021)
Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review
Javier P. Gisbert et al.
DRUGS (2020)
Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group
Uma Mahadevan et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2019)
Exposure to Vedolizumab in IBD Pregnant Women Appears of Low Risk for Mother and Neonate: A First Prospective Comparison Study
Ariella Bar-Gil Shitrit et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2019)
Continuous Anti-TNFα Use Throughout Pregnancy: Possible Complications For the Mother But Not for the Fetus. A Retrospective Cohort on the French National Health Insurance Database (EVASION)
Maxime Luu et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)
Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study
M. Chaparro et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)
Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis
Uma Mahadevan et al.
INFLAMMATORY BOWEL DISEASES (2018)
Drug Safety and Risk of Adverse Outcomes for Pregnant Patients With Inflammatory Bowel Disease
Uma Mahadevan et al.
GASTROENTEROLOGY (2017)
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Acute severe ulcerative colitis: from pathophysiology to clinical management
Pieter Hindryckx et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2016)
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
B. G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study
Martin Bortlik et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2013)
Pathogenesis of calcineurin inhibitor-induced hypertension
Ewout J. Hoorn et al.
JOURNAL OF NEPHROLOGY (2012)
Pathogenesis and management of hypertension after kidney transplantation
Christos Chatzikyrkou et al.
JOURNAL OF HYPERTENSION (2011)
Crohn's Disease Is a Risk Factor for Preterm Birth
Olof Stephansson et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2010)
Cyclosporine Treatment of Steroid-Refractory Ulcerative Colitis During Pregnancy
Julien Branche et al.
INFLAMMATORY BOWEL DISEASES (2009)
Pregnancy outcomes in women with inflammatory bowel disease: A large community-based study from Northern California
Uma Mahadevan et al.
GASTROENTEROLOGY (2007)
A meta-analysis on the influence of inflammatory bowel disease on pregnancy
J. Cornish et al.
GUT (2007)
Cyclosporine, tacrolimus, and mycophenolate mofetil in the treatment of inflammatory bowel disease
CG Loftus et al.
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2004)
Oral cyclosporine but not tacrolimus reduces renal transplant blood flow
BJ Nankivell et al.
TRANSPLANTATION (2004)
Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects
IHHT Klein et al.
TRANSPLANTATION (2002)